Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olsson

Showing results (581-590 of 632) with videos related to

Pageof 64
Sort By:
The American Journal of Cardiology|July 21, 2010
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)Terje R Pedersen, Nilo B Cater, Ole Faergeman, et al.
Clinical Obesity|February 26, 2022
Family-based treatment of children with severe obesity in a public healthcare setting: Results from a randomized controlled trialHanna F Skjåkødegård, Rachel P K Conlon, Sigurd W Hystad, et al.
The New England Journal of Medicine|September 9, 1999
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study GroupM M Samama, A T Cohen, J Y Darmon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 22, 2016
Modeling Strategies for Quantification of In Vivo <sup>18</sup>F-AV-1451 Binding in Patients with Tau PathologyAndreas Hahn, Martin Schain, Maria Erlandsson, et al.
The American Journal of Cardiology|February 24, 2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)Matti J Tikkanen, Ingar Holme, Nilo B Cater, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
European Journal of Heart Failure|August 19, 2007
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trialLars G Olsson, Karl Swedberg, John G F Cleland, et al.
Trials|July 26, 2022
The e-mental health treatment in Stockholm myocardial infarction with non-obstructive coronaries or Takotsubo syndrome study (E-SMINC): a study protocol for a randomised controlled trialErik M G Olsson, Fredrika Norlund, Elisabet Rondung, et al.
The American Journal of Cardiology|September 18, 2004
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering studyTerje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|March 27, 2009
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme, Michael Szarek, Nilo B Cater, et al.
Pageof 64

Showing results (581-590 of 632) with videos related to

Sort By:
Pageof 64
The American Journal of Cardiology|July 21, 2010
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)Terje R Pedersen, Nilo B Cater, Ole Faergeman, et al.
Clinical Obesity|February 26, 2022
Family-based treatment of children with severe obesity in a public healthcare setting: Results from a randomized controlled trialHanna F Skjåkødegård, Rachel P K Conlon, Sigurd W Hystad, et al.
The New England Journal of Medicine|September 9, 1999
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study GroupM M Samama, A T Cohen, J Y Darmon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 22, 2016
Modeling Strategies for Quantification of In Vivo <sup>18</sup>F-AV-1451 Binding in Patients with Tau PathologyAndreas Hahn, Martin Schain, Maria Erlandsson, et al.
The American Journal of Cardiology|February 24, 2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)Matti J Tikkanen, Ingar Holme, Nilo B Cater, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
European Journal of Heart Failure|August 19, 2007
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trialLars G Olsson, Karl Swedberg, John G F Cleland, et al.
Trials|July 26, 2022
The e-mental health treatment in Stockholm myocardial infarction with non-obstructive coronaries or Takotsubo syndrome study (E-SMINC): a study protocol for a randomised controlled trialErik M G Olsson, Fredrika Norlund, Elisabet Rondung, et al.
The American Journal of Cardiology|September 18, 2004
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering studyTerje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|March 27, 2009
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme, Michael Szarek, Nilo B Cater, et al.
Pageof 64